Journey Medical Corporation announced data from a comparative bioavailability (bridging) study of DFD-29 (Minocycline Hydrochloride Modified Release Capsules, 40 mg) vs. Solodyn®? (Minocycline Hydro chloride Extended-Release Tablets, 105 mg).

DFD-29 is being developed for the treatment of rosacea in collaboration with Dr. Reddy's Laboratories Ltd. The data were presented at the 43rd Annual Fall Clinical Dermatology Conference taking place in Las Vegas, NV. Given the previously reported positive results from two Phase 3 clinical trials of DFD-29, The company anticipates submitting a New Drug Application to the FDA by the end of this year. If approved, DFD-29 will be the lowest-dose minocycline on the market and may create a paradigm shift in how rosacea is treated in the millions of patients suffering from this condition.